Tekla Life Sciences Investors

NYSE:HQL

Asset Management

Financial Services
$19.27 +0.62%

+$0.11 today

Market cap
$585.96M
Beta
0.73
P/E (TTM)
2.8
EPS (TTM)
$6.52
Dividend yield
11.35%
52W Low $12.34High $18.46

Volume 0.12M

Average 0.11M

HQL Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Tekla Life Sciences InvestorsNYSE: HQL

Weighted Avg Shares · Q2 FY2026 · quarter ended Mar 2026

Weighted avg shares grows 5.3% year over year

Q2 FY2026 weighted avg shares of 30.41M shares rose 5.3% year over year. Over 3 fiscal years it compounded at +4.0% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
30.41M— QoQ
Last fiscal yearSep 2025
28.87M+2.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.3%——
1 year+2.9%——
3-year CAGR+4.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
28.87M USD
Year-over-year change
+2.9%
4-year CAGR
+4.4%

Weighted Avg Shares vs competitors

How HQL compares with its peers on the latest reported figures

  • HQL's FY2025 weighted avg shares of 28.87M shares is the 7th highest of the 10 companies compared; the peer median is 38.71M shares.
  • Its year-over-year change of +2.9% is the 3rd highest of 10, against a peer median of +0.2%.
  • Over three fiscal years its annual growth of +4.0% compares with a peer median of +5.1%.
HQL Competitors Peer median
Weighted Avg Shares for HQL and competitors
Company Period LTM YoY 3-year CAGR
ECCEagle Point Credit Company Inc.LTM Dec 2025123.09M +24.2%+39.8%
TCPCBlackRock TCP Capital Corp.LTM Mar 202684.85M -0.6%+13.7%
PNNTPennantPark Investment CorporationLTM Mar 202664.63M -1.1%+0.0%
CIONCION Investment CorporationLTM Mar 202651.96M -2.7%-2.5%
GAINGladstone Investment CorporationLTM Mar 202638.71M +5.5%+5.1%
CCAPCrescent Capital BDC, Inc.LTM Mar 202637.02M -0.1%+6.2%
HQLTekla Life Sciences InvestorsFY202528.87M +2.9%+4.0%
GLADGladstone Capital CorporationLTM Mar 202622.49M +2.1%+9.2%
MCIBarings Corporate InvestorsLTM Jun 202520.44M +0.7%+0.6%
SORSource Capital, Inc.FY20258.22M +0.2%-0.6%
Peer median (excluding HQL) 38.71M+0.2%+5.1%

Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue45.02M31.86M39.39M86.69M86.39M
Cost of Revenue6.08M5.55M5.24M5.36M4.97M
Gross Profit38.95M26.31M18.28M86.69M86.39M
Gross Margin86.5%82.6%46.4%100.0%100.0%
Research & Development0(3)000
Selling, General & Admin844.02K1.08M903.14K1.33M743.17K
Operating Expenses1.16M1.35M1.17M1.39M791.57K
Depreciation & Amortization4.14M2.99M27.6M1.92M0
EBITDA68.68M(101.62M)49.95M87.22M85.59M
EBITDA Margin152.5%-318.9%126.8%100.6%99.1%
Operating Income64.53M(104.6M)(5.24M)85.3M85.59M
Operating Margin143.3%-328.3%-13.3%98.4%99.1%
Interest Income050.09K204.45K1.04M349.84K
Interest Expense00000
Other Income / Expenses(7.83K)2.42K27.6M87.22M0
Income Before Tax64.53M(104.6M)22.35M85.3M85.59M
Pre-Tax Margin143.3%-328.3%56.8%98.4%99.1%
Income Tax Expense00000
Net Income64.53M(104.6M)22.35M85.3M85.59M
Net Margin143.3%-328.3%56.8%98.4%99.1%
EPS (Basic)2.66(4.07)0.793.042.96
EPS (Diluted)2.66(4.07)0.793.042.96
Weighted Avg Shares24.26M25.68M28.29M28.06M28.87M
Weighted Avg Shares (Diluted)24.26M25.68M28.29M28.06M28.87M

Tekla Life Sciences Investors

NYSE:HQL

Intrinsic Alpha fair value

Locked

Current Price

$19.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.